Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

526
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
526
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

468
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
468
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

443
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
443
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

223
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
223
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

176
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors.

JCO oncology practice·2026
Same author

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Blood advances·2026
Same author

Nurse-Specific Assessment and Management of Neurotoxicity Associated With Immunotherapy: An Integrative Literature Review.

Journal of pediatric hematology/oncology nursing·2026
Same author

Dinutuximab-Associated Neurotoxicity: Incidence, Presentation, Risk Factors, and Nursing Interventions.

Journal of pediatric hematology/oncology nursing·2026
Same author

Using Natural Language Processing to Identify Symptomatic Adverse Events in Pediatric Oncology: Tutorial for Clinician Researchers.

JMIR bioinformatics and biotechnology·2025

Related Experiment Video

Updated: Jul 14, 2025

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

5.9K

Dose-limiting mucositis: friend or foe?

Clifton P Thornton1,2, Etan Orgel3,4

  • 1Center for Pediatric Nursing Research & Evidence-Based Practice, Nursing & Clinical Care Services, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ThorntonC3@CHOP.edu.

Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|October 7, 2023
PubMed
Summary

Cancer therapy dose-limiting toxicities, like mucositis, are common. Understanding if these toxicities impact survival or indicate a favorable prognosis is crucial for personalized cancer treatment.

Keywords:
Dose-limiting toxicitiesMucositisPediatric oncologyTherapy de-escalations

More Related Videos

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

21.2K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

Related Experiment Videos

Last Updated: Jul 14, 2025

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

5.9K
Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

21.2K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.2K

Area of Science:

  • Oncology
  • Symptom Science
  • Cancer Therapeutics

Background:

  • Dose-limiting toxicities (DLTs) are frequent in cancer therapy, often requiring treatment modification.
  • The prognostic significance of DLTs, such as mucositis, remains poorly understood.
  • Mucositis, a common DLT, has a complex etiology and unclear relationship with cancer survival.

Purpose of the Study:

  • To investigate the prognostic implications of dose-limiting toxicities in cancer therapy.
  • To explore the underlying mechanisms and population-specific variations of mucositis.
  • To determine if mucositis can serve as a predictive biomarker for treatment response and survival.

Main Methods:

  • Review of existing literature on dose-limiting toxicities and mucositis.
  • Analysis of clinical data to assess the relationship between mucositis and cancer survival.
  • Exploration of symptom science methodologies for understanding toxicity development.

Main Results:

  • Limited understanding exists regarding whether DLTs indicate poor prognosis or physiologic susceptibility.
  • Mucositis, despite being a long-recognized toxicity, has incompletely understood development and prognostic value.
  • Further research is needed to clarify the role of mucositis in cancer outcomes.

Conclusions:

  • Rigorous symptom science approaches are essential for deciphering the role of mucositis.
  • Mucositis may serve as a critical indicator of treatment response or a marker of patient susceptibility.
  • Understanding mucositis could guide personalized therapy delivery and improve cancer patient survival.